Stockscreener 앱 받기
58.61
1.68%
-1.00
시간 외 거래:
58.61
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Future Fund LLC Sells 25,199 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Principal Financial Group Inc. Has $25.65 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Janney Montgomery Scott LLC Purchases 9,995 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Artisan Partners Limited Partnership Adjusts Stake in Halozyme T - GuruFocus.com
How the (HALO) price action is used to our Advantage - Stock Traders Daily
WCM Investment Management LLC Decreases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Assetmark Inc. Has $5.33 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Needle Free Injectors Market Is Expected To Reach a Revenue Of USD 2,980.9 Million By 2033, At 8.1% CAGR: Dimension Market Research - GlobeNewswire Inc.
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Foster & Motley Inc. Makes New $609,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Trimmed by Kornitzer Capital Management Inc. KS - MarketBeat
Hanseatic Management Services Inc. Invests $581,000 in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme: Looking For More Growth Following Record Q3 Earnings (NASDAQ:HALO) - Seeking Alpha
Catalyst Capital Advisors LLC Invests $1.94 Million in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme stock price target, rating held on earnings beat By Investing.com - Investing.com Canada
H.C. Wainwright lifts Halozyme stock target, buy rating on strong earnings - Investing.com Canada
Halozyme Therapeutics (NASDAQ:HALO) Given New $52.00 Price Target at Piper Sandler - MarketBeat
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Assenagon Asset Management S.A. Sells 40,070 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Results: Halozyme Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up - MSN
VELA Investment Management LLC Makes New $729,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q3 2024 Earnings Call Transcript - Insider Monkey
(HALO) Technical Data - Stock Traders Daily
Halozyme Announces Record Earnings, Guidance - Yahoo Finance
Earnings call: Halozyme raises full-year guidance on strong Q3 performance - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) Shares Gap Up After Analyst Upgrade - MarketBeat
JMP Securities Raises Halozyme Therapeutics (NASDAQ:HALO) Price Target to $73.00 - MarketBeat
Stephens Investment Management Group LLC Sells 62,174 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say - MSN
Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Halozyme Therapeutics Reports Strong Q3 2024 Results - TipRanks
Halozyme Therapeutics: Q3 Earnings Snapshot - CT Insider
Halozyme Therapeutics Shares Climb As it Raises FY Outlook - MarketWatch
Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates - Yahoo Finance
Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024 - Marketscreener.com
Congress Asset Management Co. Grows Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Halozyme Therapeutics Q3 2024 Earnings Preview - MSN
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Sees Large Increase in Short Interest - MarketBeat
A Look Ahead: Halozyme Therapeutics's Earnings Forecast - Benzinga
Halozyme Therapeutics : to Present at Upcoming Investor Conferences - Marketscreener.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by International Assets Investment Management LLC - MarketBeat
Analysts Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $60.44 - MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Davidson Capital Management Inc. - MarketBeat
Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet - Simply Wall St
Arbor Investment Advisors LLC Takes $1.03 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
Creative Planning Has $2.68 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - Defense World
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Holdings Boosted by Raymond James & Associates - MarketBeat
Mount Yale Investment Advisors LLC Purchases New Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) - MarketBeat
HC Wainwright Reiterates Buy Rating for Halozyme Therapeutics (NASDAQ:HALO) - MarketBeat
Unveiling 12 Analyst Insights On Halozyme Therapeutics - Benzinga
Halozyme maintains 2024 revenue forecast despite patent revocation By Investing.com - Investing.com Australia
6.21%
0.93%
자본화:
|
볼륨(24시간):